Epigenetic regulation of IGF2/IGFBP7 signalling in anxiety disorders and neurodegenerative diseases

• Antragsteller: Professor Dr. André Fischer, seit 7/2013
• Fachliche Zuordnung: Molekulare Biologie und Physiologie von Nerven- und Gliazellen
• Förderung: Förderung von 2013 bis 2017
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 235374648

Anxiety disorders (PTSD) and neurodegenerative diseases (Alzheimers disease) are an increasing problem to our societies. The underlying molecular mechanisms of such diseases are only poorly understood. Both diseases are associated with a severe cognitive impairment. Moreover, PTSD and amyloid pathology are also risk factors for age-related cognitive decline (or dementia). Recent studies suggest a bond between both risk factors that could accelerate the progression of dementia. However, the nature of this bond is still unclear. Recent publications and data from our lab indicate that epigenetic gene regulation of IGF signaling (eg. IGF2/IGFBP7) might play an important role in fear extinction and age-associated memory impairment. Others and we have suggested that therapeutic strategies that target IGF2 signaling and adult neurogenesis might be suitable to treat these diseases. Therefore, to understand the nature of such epigenetic regulation of IGF signaling is crucial. My research would combine multiple approaches such as molecular, pharmacological, histological, and behavioral techniques in disease animal models. The use of array and high-throughput sequencing technologies will also help to screen for potential biomarkers and therapeutic targets for age-associated cognitive diseases.

• DFG-Verfahren: Sachbeihilfen
• Ehemaliger Antragsteller: Dr. Roberto Carlos Agis-Balboa, bis 7/2013